Management of systemic sclerosis: British Society for Rheumatology guideline scope

Christopher P. Denton; Enrico De Lorenzis; Elen Roblin; Nina Goldman; Begonya Alcacer-Pitarch; Emma Blamont; Maya Buch; Maresa Carulli; Caroline Cotton; Francesco Del Galdo; Emma Derrett-Smith; Karen Douglas; Sue Farrington; Kim Fligelstone; Luke Gompels; Bridget Griffiths; Ariane Herrick; Michael Hughes; Clare Pain; Georgina Pantano; John Pauling; Athiveeraramapandian Prabu; Nuala O'donoghue; Elisabetta Renzoni; Jeremy Royle; Muditha Samaranayaka; Julia Spierings; Aoife Tynan; Louise Warburton; Voon Ong

doi:10.1093/rap/rkad022

Management of systemic sclerosis: British Society for Rheumatology guideline scope

Christopher P. Denton^*, Enrico De Lorenzis, Elen Roblin, Nina Goldman, Begonya Alcacer-Pitarch, Emma Blamont, Maya Buch, Maresa Carulli, Caroline Cotton, Francesco Del Galdo, Emma Derrett-Smith, Karen Douglas, Sue Farrington, Kim Fligelstone, Luke Gompels, Bridget Griffiths, Ariane Herrick, Michael Hughes, Clare Pain, Georgina PantanoJohn Pauling, Athiveeraramapandian Prabu, Nuala O'donoghue, Elisabetta Renzoni, Jeremy Royle, Muditha Samaranayaka, Julia Spierings, Aoife Tynan, Louise Warburton, Voon Ong

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

2 Downloads (Pure)

Abstract

This guideline will provide a practical roadmap for management of SSc that builds upon the previous treatment guideline to incorporate advances in evidence-based treatment and increased knowledge about assessment, classification and management. General approaches to management as well as treatment of specific complications will be covered, including lung, cardiac, renal and gastrointestinal tract disease, as well as RP, digital vasculopathy, skin manifestations, calcinosis and impact on quality of life. It will include guidance related to emerging approved therapies for interstitial lung disease and account for National Health Service England prescribing policies and national guidance relevant to SSc. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence accreditation.

Original language	English
Article number	rkad022
Number of pages	5
Journal	Rheumatology advances in practice
Volume	7
Issue number	1
DOIs	https://doi.org/10.1093/rap/rkad022
Publication status	Published - 14 Mar 2023

Keywords

guideline
management
pulmonary fibrosis
scleroderma
SSc

Access to Document

10.1093/rap/rkad022Licence: CC BY

rkad022Final published version, 603 KBLicence: CC BY

Cite this

Denton, C. P., De Lorenzis, E., Roblin, E., Goldman, N., Alcacer-Pitarch, B., Blamont, E., Buch, M., Carulli, M., Cotton, C., Del Galdo, F., Derrett-Smith, E., Douglas, K., Farrington, S., Fligelstone, K., Gompels, L., Griffiths, B., Herrick, A., Hughes, M., Pain, C., ... Ong, V. (2023). Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatology advances in practice, 7(1), Article rkad022. https://doi.org/10.1093/rap/rkad022

@article{a69b82467afc41d98b1995fa91cf1ce2,

title = "Management of systemic sclerosis: British Society for Rheumatology guideline scope",

abstract = "This guideline will provide a practical roadmap for management of SSc that builds upon the previous treatment guideline to incorporate advances in evidence-based treatment and increased knowledge about assessment, classification and management. General approaches to management as well as treatment of specific complications will be covered, including lung, cardiac, renal and gastrointestinal tract disease, as well as RP, digital vasculopathy, skin manifestations, calcinosis and impact on quality of life. It will include guidance related to emerging approved therapies for interstitial lung disease and account for National Health Service England prescribing policies and national guidance relevant to SSc. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence accreditation.",

keywords = "guideline, management, pulmonary fibrosis, scleroderma, SSc",

author = "Denton, {Christopher P.} and {De Lorenzis}, Enrico and Elen Roblin and Nina Goldman and Begonya Alcacer-Pitarch and Emma Blamont and Maya Buch and Maresa Carulli and Caroline Cotton and {Del Galdo}, Francesco and Emma Derrett-Smith and Karen Douglas and Sue Farrington and Kim Fligelstone and Luke Gompels and Bridget Griffiths and Ariane Herrick and Michael Hughes and Clare Pain and Georgina Pantano and John Pauling and Athiveeraramapandian Prabu and Nuala O'donoghue and Elisabetta Renzoni and Jeremy Royle and Muditha Samaranayaka and Julia Spierings and Aoife Tynan and Louise Warburton and Voon Ong",

note = "Funding Information: This work was supported by the British Society for Rheumatology. Publisher Copyright: {\textcopyright} 2023 The Author(s).",

year = "2023",

month = mar,

day = "14",

doi = "10.1093/rap/rkad022",

language = "English",

volume = "7",

journal = "Rheumatology advances in practice",

issn = "2514-1775",

publisher = "Oxford University Press",

number = "1",

}

Denton, CP, De Lorenzis, E, Roblin, E, Goldman, N, Alcacer-Pitarch, B, Blamont, E, Buch, M, Carulli, M, Cotton, C, Del Galdo, F, Derrett-Smith, E, Douglas, K, Farrington, S, Fligelstone, K, Gompels, L, Griffiths, B, Herrick, A, Hughes, M, Pain, C, Pantano, G, Pauling, J, Prabu, A, O'donoghue, N, Renzoni, E, Royle, J, Samaranayaka, M, Spierings, J, Tynan, A, Warburton, L & Ong, V 2023, 'Management of systemic sclerosis: British Society for Rheumatology guideline scope', Rheumatology advances in practice, vol. 7, no. 1, rkad022. https://doi.org/10.1093/rap/rkad022

TY - JOUR

T1 - Management of systemic sclerosis

T2 - British Society for Rheumatology guideline scope

AU - Denton, Christopher P.

AU - De Lorenzis, Enrico

AU - Roblin, Elen

AU - Goldman, Nina

AU - Alcacer-Pitarch, Begonya

AU - Blamont, Emma

AU - Buch, Maya

AU - Carulli, Maresa

AU - Cotton, Caroline

AU - Del Galdo, Francesco

AU - Derrett-Smith, Emma

AU - Douglas, Karen

AU - Farrington, Sue

AU - Fligelstone, Kim

AU - Gompels, Luke

AU - Griffiths, Bridget

AU - Herrick, Ariane

AU - Hughes, Michael

AU - Pain, Clare

AU - Pantano, Georgina

AU - Pauling, John

AU - Prabu, Athiveeraramapandian

AU - O'donoghue, Nuala

AU - Renzoni, Elisabetta

AU - Royle, Jeremy

AU - Samaranayaka, Muditha

AU - Spierings, Julia

AU - Tynan, Aoife

AU - Warburton, Louise

AU - Ong, Voon

PY - 2023/3/14

Y1 - 2023/3/14

N2 - This guideline will provide a practical roadmap for management of SSc that builds upon the previous treatment guideline to incorporate advances in evidence-based treatment and increased knowledge about assessment, classification and management. General approaches to management as well as treatment of specific complications will be covered, including lung, cardiac, renal and gastrointestinal tract disease, as well as RP, digital vasculopathy, skin manifestations, calcinosis and impact on quality of life. It will include guidance related to emerging approved therapies for interstitial lung disease and account for National Health Service England prescribing policies and national guidance relevant to SSc. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence accreditation.

AB - This guideline will provide a practical roadmap for management of SSc that builds upon the previous treatment guideline to incorporate advances in evidence-based treatment and increased knowledge about assessment, classification and management. General approaches to management as well as treatment of specific complications will be covered, including lung, cardiac, renal and gastrointestinal tract disease, as well as RP, digital vasculopathy, skin manifestations, calcinosis and impact on quality of life. It will include guidance related to emerging approved therapies for interstitial lung disease and account for National Health Service England prescribing policies and national guidance relevant to SSc. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence accreditation.

KW - guideline

KW - management

KW - pulmonary fibrosis

KW - scleroderma

KW - SSc

UR - http://www.scopus.com/inward/record.url?scp=85160596861&partnerID=8YFLogxK

U2 - 10.1093/rap/rkad022

DO - 10.1093/rap/rkad022

M3 - Review article

C2 - 36923262

SN - 2514-1775

VL - 7

JO - Rheumatology advances in practice

JF - Rheumatology advances in practice

IS - 1

M1 - rkad022

ER -

Management of systemic sclerosis: British Society for Rheumatology guideline scope

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this